Is coronary thrombolysis associated with side effects that significantly compromise clinical benefits?

This publication has 27 references indexed in Scilit:

• New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction
  Journal of the American College of Cardiology, 1994
• Primary coronary angioplasty for acute myocardial infarction (the primary angioplasty registry)
  The American Journal of Cardiology, 1994
• An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction
  New England Journal of Medicine, 1993
• ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction
  Published by Elsevier ,1992
• In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin
  The Lancet, 1990
• THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTY
  The Lancet, 1988
• A Randomized Trial of Immediate versus Delayed Elective Angioplasty after Intravenous Tissue Plasminogen Activator in Acute Myocardial Infarction
  New England Journal of Medicine, 1987
• Activation of the complement system by recombinant tissue plasminogen activator
  Journal of the American College of Cardiology, 1987
• Status of the myocardium and infarct-related coronary artery in 19 necropsy patients with acute recanalization using pharmacologic (streptokinase, r-tissue plasminogen activator), mechanical (percutaneous transluminal coronary angioplasty) or combined types of reperfusion therapy
  Journal of the American College of Cardiology, 1987
• Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis
  Journal of the American College of Cardiology, 1986